ChromaDex’s NIAGEN® (Patented Nicotinamide Riboside, NR), the Most Efficient and High-Quality NAD+ Precursor, Featured in New Solgar® Cellular Nutrition Cellular Energy Supplement
New ingredient collaboration debuts Solgar’s first NAD + boosting supplement and reinforces NIAGEN as the gold standard in the NAD + supplement category
“NIAGEN NR is a testament to our dedication to the highest scientific rigor and quality standards. This ingredient partnership with Nestlé Health Science and
NAD+ is an essential coenzyme that plays a vital role in cellular functions, including mitochondrial function, cellular energy production, and DNA repair. NIAGEN NR, the most efficient NAD+ precursor, is backed by two Nobel Prize winners, 30+ human clinical studies, 300 published scientific studies, has been accepted by the world’s most rigorous regulatory bodies, and 300mg of NIAGEN NR is clinically shown to increase NAD+ by over 50% in two weeks.
Solgar Cellular Energy features 300mg of NIAGEN NR to support cell energy, repair, and vitality. Solgar Cellular Energy helps renew the body’s natural ability to transform nutrients into energy – the energy cells need each day. In addition to NIAGEN NR, the product features a blend of six B vitamins (B1, B2, B6, B12, Biotin, and Pantothenic Acid) and vitamin C for immune, heart, and nerve health, delivering a holistic approach to healthy aging.
ChromaDex’s
Solgar’s Cellular Energy supplement featuring NIAGEN NR is available as part of a suite of Cellular Nutrition products. To read more about the science supporting NIAGEN NR visit www.chromadex.com and for more information on the Solgar Cellular Nutrition Cellular Energy product featuring NIAGEN NR, please visit www.solgar.com/cellular-nutrition.
About
NIAGEN NR is the active ingredient in ChromaDex’s consumer products, sold as the brand Tru Niagen®, the number one healthy-aging NAD+ supplement in
*Based on the top-selling dietary supplement brands by revenue per the largest
Forward-Looking Statements:
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended, including statements related to Solgar Cellular Nutrition Cellular Energy Supplement marking a significant milestone in the health and wellness industry. Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as "expects," "anticipates," "intends," "estimates," "plans," "potential," "possible," "probable," "believes," "seeks," "may," "will," "should," "could" or the negative of such terms or other similar expressions. Risks that contribute to the uncertain nature of these forward-looking statements include the impact of the COVID-19 pandemic on our business and the global economy; our history of operating losses and need to obtain additional financing; the growth and profitability of our product sales; our ability to maintain sales, marketing and distribution capabilities; changing consumer perceptions of our products; our reliance on a single or limited number of third-party suppliers; and the risks and uncertainties associated with our business and financial condition. More detailed information about
Source:
*These statements have not been evaluated by the
View source version on businesswire.com: https://www.businesswire.com/news/home/20240430870400/en/
ChromaDex Media Contact:
310-388-6706 ext. 689
kendall.knysch@chromadex.com
ChromaDex Investor Relations Contact:
+1 (949) 356-1620
InvestorRelations@ChromaDex.com
Source: